Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancer

被引：0

作者：

Lee, J. ^{[1
]}

Ajani, J. A. ^{[2
]}

Chung, H. C. ^{[3
]}

Kang, Y-K. ^{[4
]}

Iqbal, S. ^{[5
]}

Allen, S. ^{[6
]}

Al-Sakaff, N. ^{[7
]}

Decalf, J. ^{[8
]}

Li, S. ^{[9
]}

Pintoffl, J. ^{[7
]}

Sayyed, P. ^{[7
]}

Bang, Y-J. ^{[10
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Oncol, Seoul, South Korea

[2] MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[5] USC Norris Comprehens Canc Ctr, Dept Oncol, Los Angeles, CA USA

[6] Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA

[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland

[8] Genentech Inc, Dept Canc Immunol, South San Francisco, CA USA

[9] Biostat Roche China Holding Ltd, Shanghai, Peoples R China

[10] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1491

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1382P

引用

页码：S1047 / S1047

页数：1

共 50 条

[1] Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) plus etrumadenant (etruma) plus chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC
Kim, Kyu-Pyo
Sarvise, Mariano Ponz
Macarulla, Teresa
Alistar, Angela
O'Reilly, Eileen
Boakye, Mathew
Prizant, Hen
Xu, Trista
Young, Fiona
Lau, Janet
Oh, Do-Youn
Lacy, Jill
CANCER RESEARCH, 2024, 84 (07)
[2] PHASE IB/II OPEN-LABEL, RANDOMIZED EVALUATION OF ATEZOLIZUMAB (ATEZO) plus SELICRELUMAB (SELI) plus GEMCITABINE plus NAB-PACLITAXEL (GEM plus NABP) OR BEVACIZUMAB (BEV) VS CONTROL IN MORPHEUS-PDAC, -TNBC AND -CRC
Manji, Gulam
Bahary, Nathan
Chung, Vincent
Dalenc, Florence
Ducreux, Michel
Gomez-Roca, Carlos
Im, Seock-Ah
Kortmansky, Jeremy
Lacy, Jill
Segal, Neil
Tredan, Olivier
Cirovic, Olivera
DuPree, Kelly
Lenain, Christelle
Lu, Danny
Robert, Lidia
Xu, Jeffrey
Zhang, Xiaosong
Kim, Sung-Bae
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A157 - A158
[3] phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS-pancreatic ductal adenocarcinoma
Chung, V.
Alistar, A.
George, B.
Kim, K.
Kindler, H.
Oh, D.
Allen, S.
Barak, H.
Ci, B.
Lau, J.
Retiere, A.
Shemesh, C.
Teichgraber, V.
Zhang, X.
Lopez, C.
ANNALS OF ONCOLOGY, 2020, 31 : S218 - S218
[4] Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Fakih, Marwan
Cleary, James M.
Hong, Yong Sang
Kim, Tae-You
Safyan, Rachael A.
Allen, Simon
Bailey, Lorna
Cha, Edward
Lenain, Christelle
Lu, Danny
Schulze, Jochen
Shemesh, Colby S.
Zimmermann, Stefan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) plus atezolizumab (atezo) plus chemotherapy (CT) in patients (pts) with esophageal cancer (EC).
Sun, Jong-Mu
Chao, Yee
Kim, Sung-Bae
Rha, Sun Young
Evans, T. R. Jeffry
Strickland, Andrew
Chau, Ian
Pelles-Avraham, Sharon
Ajani, Jaffer A.
Malhotra, Ritu
Liu, Qingyuan
Li, Sijing
Cha, Edward
Rahalkar, Swapna
Allen, Simon
Hsu, Chih-Hung
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 324 - 324
[6] Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Felip, E.
Lim, F. L.
Johnson, M.
O'Brien, M.
Barlesi, F.
Mazieres, J.
Solomon, B.
Moreno, V.
Boni, V.
Swalduz, A.
Goldberg, S.
Keam, B.
Allen, S.
Helms, H-J.
Shemesh, C.
Pintoffl, J.
Al-Sakaff, N.
Bailey, L.
Sayyed, P.
Cho, B. C.
ANNALS OF ONCOLOGY, 2020, 31 : S850 - S850
[7] Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) plus entinostat (entino) in MORPHEUS-HR plus breast cancer (M-HR plus BC)
Sonnenblick, A.
Im, S-A.
Lee, K. S.
Tan, A.
Telli, M.
Shachar, S. Strulov
Tchaleu, F. Bene
Cha, E.
DuPree, K.
Nikanjam, M.
Shemesh, C.
Xu, J.
Zhang, X.
Zhu, J.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2021, 32 : S479 - S479
[8] Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.
Desai, Jayesh
Fakih, Marwan
Pedersen, Katrina Sophia
Hong, Yong Sang
Segal, Neil Howard
Allen, Simon
Bailey, Lorna
Lenain, Christelle
Lu, Danny
Sayyed, Pakeeza Zahra
Schulze, Jochen
Cecchini, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[9] Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR plus breast cancer (M-HR plus BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)
Hurvitz, Sara A.
Boni, Valentina
Comen, Elizabeth
Im, Seock-Ah
Jung, Kyung Hae
Kim, Sung-Bae
Lee, Keun Seok
Loi, Sherene
Rugo, Hope S.
Sonnenblick, Amir
Telli, Melinda L.
DuPree, Kelly
Fasso, Marcella
Lin, Ya-Chen
Nikanjam, Mina
Schimmoller, Frauke
Zhang, Xiaosong
CANCER RESEARCH, 2022, 82 (04)
[10] Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)
Oh, Do-Youn
Ajani, Jaffer A.
Bang, Yung-Jue
Chung, Hyun Cheol
Lacy, Jill
Lee, Jeeyun
Macarulla, Teresa
Manji, Gulam Abbas
O'Reilly, Eileen Mary
Allen, Simon
Al-Sakaff, Nedal Jaffer Abdulla
Barak, Hila
Patel, Jilpa
Pintoffl, Jan Peter
Shemesh, Colby
Zhang, Wei
Zhang, Xiaosong
Chau, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →